Clinical study of nasal irrigation and budesonide nasal spray in the treatment of vasomotor rhinitis
Lin LIN,Qian LU,Xinyue TANG,Fei DAI,Jinjin WEI
DOI: https://doi.org/10.16542/j.cnki.issn.1007-4856.2017.03.013
2017-01-01
Abstract:Objective Vasomotor rhinitis (VMR) is a common disease that is unrelated to allergy and infection. The exact pathogenesis of VMR is not clear. Effective long-term treatments for VMR have not been found to date. This paper compared the curative effect of nasal irrigation and budesonide nasal spray in the treatment of vasomotor rhinitis, aimed to select a long-term and effevtive treatment. Methods 101 patients with VMR were randomly divided into 4 groups. The mean age was 40.75±13.46 years old for the control group (range, 19~61 years old; 13 male, 11 female; n=24), 41.16 ±13.56 years old for the budesonide nasal spray treatment group (budesonide group) (range, 18~66 years old;13 male, 12 female;n=25), 43.88 ±9.27 years old for the nasal irrigation treatment group (nasal irrigation group) (range, 19~66 years old; 14 male, 11 female; n=25) and 43.59 ±11.40 years old for the budesonide nasal spray + nasal irrigation group (combined treatment group) (range, 20~64 years old; 13 male, 14 female; n=27). The control group patients were left untreated. Budesonide group took budesonide nasal spray treatment (each 2 sprays per nostril, 1 times daily), nasal irrigation group used 3.0% saline with a temperature of 40°C irrigate the nasal. Combined treatment group were given both treatments. The duration of the intervention period was 3 months (90 days). Visual Analog Scale (VAS) was used to evaluate nasal symptoms and the health-related quality of life was assessed with the 12-item Short Form Health Survey version 2.0 (SF-12v2). Results 90 VMR patients completed the study. At the end of the third month, the VAS score (t=5.690, P<0.0001) (t=7.054, P<0.0001) was diminished and SF-12v2 score (t=3.660, P<0.001) (t=4.971, P<0.0001) was elevated in nasal irrigation and combined treatment group versus control group, but there were no significant differences (t=1.247, P>0.05, t=1.910, P>0.05) between budesonide and control group. In addition, there were statistically significant differences between nasal irrigation (t=4.055, P<0.001, t=2.233, P<0.05) or combined (t=5.460, P<0.0001, t=3.714, P<0.001) treatment group and budesonide group, but no statistical differences (t=1.814, P>0.05, t=1.257, P>0.05) were found between nasal irrigation and combined treatment group. Conclusion Simple budesonide nasal spray is not an appropriate long-term treatment for VMR. Nasal irrigation or combined treatment of budesonide with nasal irrigation may be an appropriate therapy.